Patent application number | Description | Published |
20100173849 | NEO-TRYPTOPHAN - Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, or NT77. | 07-08-2010 |
20110183885 | NEO-TRYPTOPHAN - Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, or NT77. | 07-28-2011 |
20120108519 | NEO-TRYPTOPHAN - Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, or NT77. | 05-03-2012 |
20130210740 | NEO-TRYPTOPHAN - Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, or NT77. | 08-15-2013 |
Patent application number | Description | Published |
20100280127 | INHIBITING NEUROTRANSMITTER REUPTAKE - This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. | 11-04-2010 |
20110021471 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION - This document relates to methods and materials for reducing Aβ42 levels, reducing Aβ aggregation, or reducing both Aβ42 levels and Aβ aggregation. For example, this document provides methods and materials related to the use of agents (e.g., 5β-cholanic acid) to reduce Aβ42 levels and to reduce Aβ aggregation in mammals. | 01-27-2011 |
20110105781 | Process for the Synthesis of Long-Chain Fatty Acids - This invention relates to processes for preparing long-chain fatty acids of Formula I: | 05-05-2011 |
20120107248 | IMAGING GASTROINTESTINAL VOLUMES AND MOTILITY - This disclosure relates to contrast agents and compositions comprising the same that are capable of blocking the hydrogen/potassium adenosine triphosphatase enzyme system, and more particularly to the use of such compositions for imaging stomach and colon volume and motility. | 05-03-2012 |
20120220665 | Inhibiting Neurotransmitter Reuptake - This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. | 08-30-2012 |
20130059864 | INHIBITING NEUROTRANSMITTER REUPTAKE - This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. | 03-07-2013 |